1. 1
REDEFINING CANCER CARE

2. 2
~ $35B personalized cancer gene
profiling market by 2018
*
* Markets and Markets (2013) 2

3. 3
Big data problem
How to use
information from
cancer gene
profiling to truly
personalize
therapy
3

4. 4
Billions
540,000+
1 size
Too many combinations to evaluate?
of mutation profiles
unique single, double &
triple drug combos from
just 150 drugs
does not fit all!
4

5. 5
Our solution…
Uses gene profile of
patient’s tumor to
evaluate full range of
available therapies
Programmable
computer
simulation of a
human cancer cell
R O S A L I N DR O S A L I N D

6. 6
~100 core
processors
10,878*
simulations
Results in
< 2 hours
* All possible single drugs and 2 drug combinations for 147 drugs
Advantages of ROSALIND
 Comprehensiveness
and speed

7. 7
Advantages of ROSALIND
 Safety: Simulate rather than experiment
 Efficiency: Assign patients to most
appropriate therapy or clinical trial when
predicted optimal therapies are not yet
available

8. 8
Our vision
More personalized
cancer treatments
Higher remission
rates + lower cost of
cancer therapy
8

9. 9
Potential revenue models
 Patient-based model
 Software as a Service
 Online service: web
portal

10. 10
Patient-based model
0.1% market:
$1.6 million
1% market:
$16.4 million
5% market:
$81.9 million
10% market:
$163.9 million
Assumptions:
 Analysis ordered by attending MD
 Cost ~$1,000 per patient
 ~1.6 million new cases annually in US

11. 11
Bronze Silver Gold Platinum
Annual licensing fee
$25,000 $75,000 $150,000 $500,000
 Limited users
 Limited cases
 Medium-sized
users
 More cases
 More users
 More
features
 More cases
 Unlimited
users
 Full features
 Unlimited
cases
Software as a Service model (SaaS)

12. 12
Online service: web portal
 Serves largest population at lowest cost with
fastest turn-around and highest security:
– Independently, either in the cloud or on secure
servers, and/or
– A version can be offered through an existing online
provider (COTI, Google, etc.)
– iTunes type of customizable billing depending on
number of drugs/combinations to be evaluated

13. 13
 ROSALIND adopted by
medical community;
demanded by patients
 ROSALIND accepted,
reimbursed, and
ultimately required,
by healthcare insurers
and payers
Realistic goals

14. 14
Actual human tumor gene
profile
 Mutations:
• Oncogenes: EGFR,
CCND1
• Tumor suppressor:
ARID1A
Example: Actual Commercial Profile
Some common therapies
for this profile could
include:
 Gefitinib
 Carboplatin
 Paclitaxel (Abraxane)
 Gemcitabine
 Irinotecan

15. 15
Actual Patient Profile (cont’d)
ROSALIND evaluated just 129 options:
 Remission is not possible with any single drug
 BUT - remission may be possible with:
 Gefitinib or Tarceva or Cetuximab or Panitumumab
+ Paclitaxel or
 Carboplatin + Paclitaxel or
 Gemcitabine + Paclitaxel or
 Irinotecan + Paclitaxel

16. 16
Thank you
For more information, please contact:
Dr. Wayne R. Danter, President & CEO
Critical Outcome Technologies, Inc.
Suite 213, 700 Collip Circle,
London, Ontario, Canada N6G 4X8
T: (519) 858-5157
E: wdanter@criticaloutcome.com

17. 17
Disclaimer
This presentation may include predictions, estimates or other information that
might be considered forward-looking. While these forward looking statements
represent COTI’s current judgment on what the future holds, they are subject to
risks and uncertainties that could cause actual results to differ materially. COTI has
based any forward-looking statements on its current expectations about future
events. Such statements are subject to risks and uncertainties including, but not
limited to, the successful implementation of COTI’s strategic plans, the acceptance
of new products, the obsolescence of existing products, the resolution of existing
and potential future patent issues, additional competition, changes in economic
conditions, and other risks described in documents COTI has filed with the Toronto
Stock Exchange and Ontario Securities Commission. You are cautioned not to place
undue reliance on these forward-looking statements, which reflect our opinion only
as of the date of this presentation.
Please keep in mind that we are not obligating ourselves to revise or publicly release
the results of any revision to these forward-looking statements in light of any new
information or future events.